TimeScale Financial’s CervoMed CRVO Stock Holding History

TimeScale Financial’s Portfolio CRVO Stock Details CRVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$30	Hold	6	–	–	﹤0.01%	622
2023 Q1	$37	Hold	6	–	–	﹤0.01%	616
2022 Q4	$48	Hold	6	–	–	﹤0.01%	581
2022 Q3	$0	Hold	6	–	–	﹤0.01%	551
2022 Q2	$0	Buy	+6	New	+$74	﹤0.01%	525

Other funds holding CRVO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

TimeScale Financial's CRVO Position: Q2 2023 in Review

TimeScale Financial held its CervoMed (CRVO) position steady in Q2 2023 at 6 shares worth $30. The position accounts for ﹤0.01% of the portfolio, ranked #622.

TimeScale Financial first reported a position in CRVO in Q2 2022 and has held it in 5 quarters since. The position peaked at $48 in Q4 2022. 11 funds tracked by Wall St. Rank hold CRVO as of Q2 2023.

TimeScale Financial held 6 shares of CervoMed worth $30 as of Q2 2023.
TimeScale Financial left its CervoMed share count unchanged in Q2 2023.
CervoMed made up ﹤0.01% of TimeScale Financial's portfolio in Q2 2023, its #622 holding.
TimeScale Financial first reported a position in CervoMed in Q2 2022 and has held it in 5 quarters since.
TimeScale Financial's CervoMed position peaked at $48 in Q4 2022.
11 funds tracked by Wall St. Rank held CervoMed as of Q2 2023.

Based on TimeScale Financial's 13F filing for Q2 2023, filed 27 Jul 2023.